Arcus Biosciences, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Arcus Biosciences, Inc. (RCUS) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 22.00 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-05
- Arcus Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 22.00M shares, a 4.27% increase year-over-year.
- Arcus Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 23.40M shares, a 3.54% increase year-over-year.
- Arcus Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 21.10M shares, a 12.23% increase year-over-year.
- Arcus Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 22.60M shares, a 20.86% increase year-over-year.
- Arcus Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 20.30M shares, a 12.78% increase from fiscal 2024.
- Arcus Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 18.00M shares, a 17.65% increase from fiscal 2023.
- Arcus Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 15.30M shares, a 13.33% increase from fiscal 2022.
- Arcus Biosciences, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 13.50M shares, a 193.48% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 22.00M shares 10-Q · filed 2026-08-05 | 22.00M shares 10-Q · filed 2026-08-05 | ||||||
| 2026-03-31 | 23.40M shares 10-Q · filed 2026-05-05 | |||||||
| 2025-12-31 | 20.30M shares 10-K · filed 2026-02-25 | |||||||
| 2025-09-30 | 21.40M shares 10-Q · filed 2025-10-28 | |||||||
| 2025-06-30 | 21.10M shares 10-Q · filed 2026-08-05 | 21.90M shares 10-Q · filed 2026-08-05 | ||||||
| 2025-03-31 | 22.60M shares 10-Q · filed 2026-05-05 | |||||||
| 2024-12-31 | 18.00M shares 10-K · filed 2026-02-25 | |||||||
| 2024-09-30 | 18.70M shares 10-Q · filed 2025-10-28 | |||||||
| 2024-06-30 | 18.80M shares 10-Q · filed 2025-08-06 | 18.80M shares 10-Q · filed 2025-08-06 | ||||||
| 2024-03-31 | 18.70M shares 10-Q · filed 2025-05-06 | |||||||
| 2023-12-31 | 15.30M shares 10-K · filed 2026-02-25 | |||||||
| 2023-09-30 | 15.80M shares 10-Q · filed 2024-11-06 | |||||||
| 2023-06-30 | 16.10M shares 10-Q · filed 2024-08-08 | |||||||
| 2023-03-31 | 16.30M shares 10-Q · filed 2024-05-08 | |||||||
| 2022-12-31 | 13.50M shares 10-K · filed 2025-02-25 | |||||||
| 2022-09-30 | 13.80M shares 10-Q · filed 2023-11-07 | 13.77M shares 10-Q · filed 2022-11-02 | ||||||
| 2022-06-30 | 13.90M shares 10-Q · filed 2023-08-07 | 13.94M shares 10-Q · filed 2022-08-03 | ||||||
| 2022-03-31 | 14.20M shares 10-Q · filed 2023-05-09 | 14.23M shares 10-Q · filed 2022-05-09 | ||||||
| 2021-12-31 | 4.60M shares 10-K · filed 2024-02-21 | 4.62M shares 10-K · filed 2022-02-23 | ||||||
| 2021-09-30 | 14.19M shares 10-Q · filed 2021-11-08 | 14.19M shares 10-Q · filed 2022-11-02 | ||||||
| 2021-06-30 | 15.34M shares 10-Q · filed 2022-08-03 | |||||||
| 2021-03-31 | 14.71M shares 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | 12.10M shares 10-K · filed 2023-02-28 | 12.07M shares 10-K · filed 2021-02-25 | ||||||
| 2020-09-30 | 3.44M shares 10-Q · filed 2021-11-08 | 10.07M shares 10-Q · filed 2021-11-08 | ||||||
| 2020-06-30 | 9.43M shares 10-Q · filed 2021-08-05 | |||||||
| 2020-03-31 | 8.36M shares 10-Q · filed 2021-05-05 | |||||||
| 2019-12-31 | 6.45M shares 10-K · filed 2022-02-23 | |||||||
| 2019-09-30 | 6.08M shares 10-Q · filed 2020-11-05 | 6.08M shares 10-Q · filed 2020-11-05 | ||||||
| 2019-06-30 | 6.37M shares 10-Q · filed 2020-08-06 | |||||||
| 2019-03-31 | 4.15M shares 10-Q · filed 2020-05-05 | |||||||
| 2018-12-31 | 2.67M shares 10-K · filed 2021-02-25 | |||||||
| 2018-09-30 | 2.86M shares 10-Q · filed 2019-11-05 | |||||||
| 2018-06-30 | 3.04M shares 10-Q · filed 2019-08-06 | |||||||
| 2018-03-31 | 3.15M shares 10-Q · filed 2019-05-02 | |||||||
| 2017-12-31 | 32.80M shares 10-K · filed 2019-03-05 | |||||||
| 2017-09-30 | 23.86M shares 10-Q · filed 2018-11-08 | |||||||
| 2017-06-30 | 23.98M shares 10-Q · filed 2018-08-06 | |||||||
| 2017-03-31 | 24.06M shares 10-Q · filed 2018-05-09 | |||||||
| 2016-12-31 | 23.64M shares 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |